Clinical trials: PD-L1 Expression
Lung Neoplasms
Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC
To evaluate the efficacy and safety of envafolimab combined with endostar in the first-line treatment of advanced Non-small Cell Lung Cancer With PD-L1 positive expression
- Trial name
- NCT05203276
- Testing
- Envafolimab, Endostar
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The First People's Hospital of Lianyungang
Lichen Planus
Assessment of PD-1 and PD-L1Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study
Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study
- Trial name
- NCT04892381
- Testing
- Skin Biopsy
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cairo University
B-cell Malignancies
Expression of CD274 (PD-L1) and CD276 in B-cell Malignancies: A Study by Flowcytometry
B-cell malignancies include a spectrum of cancers originating from abnormal B lymphocytes at different developmental stages (1) that affect the peripheral blood (PB), bone marrow (BM), and lymphatic system.
- Trial name
- NCT07515313
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Assiut University
Sepsis, Immunosuppression
Expression and the Clinical Significance of Neutrophil PD-L1 During Sepsis
Immunosuppression is the leading cause of death in septic patients. Neutrophils are classical components of innate immunology, but recent studies showed that neutrophils might display antigen presenting function and inhibit…
- Trial name
- NCT01976884
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Circulating Tumor Cells (CTCs), Immunotherapy
Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores
Head and neck cancer is ranked among the fifth to eighth most prevalent cancers worldwide and is associated with a high mortality rate.
- Conditions
- Circulating Tumor Cells (CTCs), Immunotherapy, PD-L1 Expression, Liquidbiopsies
- Trial name
- NCT07396259
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Other Skin Changes Due to Chronic Exposure to Nonionizing Radiation
SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants
The purpose of this research study is to look at how the proteins and genes in people's skin change when they're exposed to simulated sunlight.
- Trial name
- NCT06177106
- Testing
- Solar Simulated Light
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Head and Neck Squamous Cell Carcinoma, Circulating Tumor Cell
PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRT
Head and neck squamous cell carcinoma (HNSCC) is the 4th highest incidence of cancer and 6th of cancer death of the males in Taiwan.
- Trial name
- NCT05008796
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Tumor, PD-L1
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
To evaluate the potential usefulness of 68Ga-NK224 positron emission tomography/computed tomography (PET/CT) for the evaluation of PD-L1 expression in primary and/or metastatic tumors, compared with histopathological results.
- Trial name
- NCT06754345
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
Non-Small Cell Lung Cancer
Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients
Several reports have examined Programmed Death 1 (PD-1) expression on tumor-infiltrating T-cells, and its correlation with prognosis has been discussed.
- Trial name
- NCT02758314
- Testing
- Evaluation of PD-1/PDL-1 expression.
- Where
- Mexico
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Non Small Cell Lung Cancer
Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients
Evaluated the correlation between the qualitative test results of Xiamen Aide PD-L1 antibody reagent (immunohistochemistry) and the efficacy of Keytruda single-agent therapy, and the research data is used to support the…
- Trial name
- CONFIDENCE (NCT05129462)
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Hunan Province Tumor Hospital